Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0566 • ACR Convergence 2023
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
Sangeeta Sule, Olivia Lamanna, Kevin Jackson, Sun-Young Ahn, Tineer Ahmed and Julia Finkel, Children's National Hospital, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex inflammatory disease involving many organ systems. To better understand and treat SLE, two phenotypes have been proposed.…
Abstract Number: 0584 • ACR Convergence 2023
Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator
Thomas Hoyler¹, Daniel Strasser¹, Ouali Berkani², Peter Cornelisse¹, Mark Murphy¹ and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²IDORSIA, Allschwil, Switzerland
Background/Purpose: In SLE, aberrant lymphocyte activation and autoantibody production result in deposition of immune complexes and contribute to tissue damage. Cenerimod, a highly selective S1P1…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 0895 • ACR Convergence 2023
Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Chaim Putterman¹, Elise Mike² and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Johns Hopkins, Bronx, NY
Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
Abstract Number: 0914 • ACR Convergence 2023
Transcription Factor RFX1 Promotes M1 Macrophage Polarization in Systemic Lupus Erythematosus via Regulating APOBEC3A
shuang Yang¹, Pei Du¹, Sujie Jia² and Ming Zhao², ¹Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital of Central South University, Changsha, China, ²Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
Background/Purpose: Aberrant macrophage polarization is generally present in autoimmune diseases. Overwhelming M1 macrophage induces the continuous progression of inflammation, which is one of the vital…
Abstract Number: 0997 • ACR Convergence 2023
Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus
W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
Abstract Number: 1234 • ACR Convergence 2023
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity
Jaqueline de amorim¹, Simone Kishimoto¹, Paula Fernandes¹, Roberto Marini², Zahi Touma³, Hermine Brunner⁴ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil, ²Revista Brasileira de Reumatologia, Campinas, Brazil, ³University of Toronto, Toronto, ON, Canada, ⁴Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
Abstract Number: 1361 • ACR Convergence 2023
Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
Abstract Number: 1456 • ACR Convergence 2023
Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens
Ibrahim Mohamed¹, Tala El Tal², santiago arciniegas³, Stephanie Fevrier⁴, justine ledochowski⁵ and Andrea Knight⁴, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) is highly prevalent in systemic lupus erythematosus (SLE), and advanced structural magnetic resonance imaging (MRI) has revealed brain abnormalities in patients…
Abstract Number: 1473 • ACR Convergence 2023
Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades
Ansaam Daoud¹, Loai Dweik², Marina Nighat Magrey³ and Omer Pamuk⁴, ¹University Hospitals, Case Western Reserve University, Akron, OH, ²Cleveland Clinic Akron General, Akron, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH, ⁴University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: SLE is a chronic autoimmune disease and affects many organ systems. Juvenile onset disease, male sex, renal involvement, and central nervous system involvement are…
Abstract Number: 1491 • ACR Convergence 2023
Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus
Lai Wang, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
Background/Purpose: Recent research focusing on follicular helper T (Tfh) cells emphasizes its importance in autoimmune diseases, such as systemic lupus erythematosus (SLE). However, the mechanisms…
Abstract Number: 1508 • ACR Convergence 2023
Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus
Vincent Hurez¹, Krishnakant Dasika Dasika¹, Perrine Soret², Renee Myers³, Katherine Kudrycki¹, Robert Sheehan¹, Christina Friedrich1¹, Sandra Hubert², Mike Reed¹, Emiko Desvaux², Audrey Aussy², Laurence Laigle², Loubna Chadli², Florian Chassereau², Sylvain Fouliard², Glenn Gauderat² and Philippe Moingeon², ¹Rosa and Co, San Carlos, CA, ²Les Laboratoires Servier SAS, Suresnes, France, ³Les Laboratoires Servier SAS, San Carlos, France
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease that requires more specific treatments to target patient subsets. To support precision medicine approaches, we…
Abstract Number: 1615 • ACR Convergence 2023
Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations
Shivani Garg¹, Giancarlo Valiente², Lexie Kolton³, Callie Saric³, Betty Chewning⁴ and Christie M. Bartels², ¹Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI
Background/Purpose: Studies show factors including daily hydroxychloroquine (HCQ) dosing or nonadherence affect blood concentrations risking 6-fold higher lupus (or SLE) flares requiring hospitalization. Given disparities…
Abstract Number: 1836 • ACR Convergence 2023
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
Jennifer Rogers¹, Megan Clowse² and Amanda Eudy³, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Raleigh, NC
Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].